MimiVax
Buffalo
About MimiVax
MimiVax is a privately-held, clinical-stage biotechnology company that focuses on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Its vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers that enable healthcare providers to cure their patients. The company was founded in 2012 and is headquartered in Buffalo, New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $16.6M
- Last round: Series Unknown (Jan 2024)
- Website: mimivax.com
- Phone: (716) 845-8850
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/mimivax-37172 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.